Most Recent
A barrister for two units of embattled wealth manager IOOF and three senior company executives facing claims by APRA have criticised the regulator for filing a broad concise statement and no statement of claim after a three-year investigation.
A judge has denied Sanofi's bid to block Alphapharm from listing its insulin injector pen on the Pharmaceutical Benefit Scheme, saying Sanofi has not established a strong enough case of infringement to justify granting the injunction.
James Packer's Crown Resorts has won a lawsuit against the NSW government for allegedly failing to protect sweeping views of the Sydney Harbour from its planned luxury casino in the Barangaroo area.
The Australian Securities and Investments Commission has promised it will stay away from the depositions of two former Rio Tinto executives in proceedings underway in the US, as it pursues a parallel case over allegedly misleading market statements the mining company made about the reserves of a $4 billion coal acquisition.
The Commonwealth has urged the court to strike out the "inconsistent" pleadings of pharmaceutical firms Otsuka and Bristol-Myers Squibb in a patent case over the antipsychotic drug Abilify, calling them a "scandal" which could bring disrepute to the administration of justice.
A judge has taken a hatchet to Quinn Emanuel's fees and the funder's cut in a $12 million settlement of a class action against Bank of Queensland, a settlement which he previously described as one of the "worst" he'd ever seen.
The Australian Securities and Investments Commission claims Rio Tinto's former CFO was referring to the write down for the reserves for two coal assets that were part of a $4 billion acquisition of Rio Tinto Coal Mozambique when he sent an email to the company CEO in January 2012 that contained the phrase "worse by far than expected".
Bank of Queensland has lost a dispute with two insurers over coverage for a $6 million settlement of a class action brought by investors in a Ponzi scheme by jailed scammer Bradley Sherwin, with a judge shooting down the bank's argument that the class action should only be considered one claim under the policy.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi's interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.